




# PHARMACEUTICAL 2023

LIXTE BIOTECHNOLOGY HOLDINGS  
INC.  
Rank 226 of 446





# PHARMACEUTICAL 2023

## LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 226 of 446

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 43% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,560
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	395
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,423
Other Liabilities	0
Other Net Income	7.8
Other Revenues	0
Property and Equipment	0
Research and Development	1,349
Selling, General and Administrative Expense	2,548

Output Variable	Value in 1000 USD
Assets	5,560
Liabilities	395
Expenses	6,320
Revenues	0
Stockholders Equity	5,165
Net Income	-6,313
Comprehensive Net Income	-6,313
Economic Capital Ratio	86%